Welcome guest, is this your first visit? Click the "Create Account" button now to join.
Results 1 to 3 of 3
  1. #1
    aaamarxdenxcp Guest

    Default ADHXF (MC $19 M) Cancer Play with 2x Phase 3 results

    Adherex (AHX.TO).. (ADHXF) is definitely one of the cheapest Cancer Play with 2 Phase 3 who pending results for June .

    STS is a chemoprotectant being developed by Adherex to reduce or prevent hearing loss in oncology patients resulting from treatment with platinum-based chemotherapy drugs.

    Drug has Orphan Drug Status and there is no Approved treatment for this Indication . Market Cap of $19 M is really a big big joke .

    Target $8-10 within 12 months if positive phase 3 outcome in june .

    Adherex (AHX.TO).. (ADHXF)

    Market Cap: $19 M
    Cash $1.7 M (Enough Cash untill Year End)
    Price: $0.76

    Shares Out: 29.1 M
    Float: 7 M

  2. Default

    Two late stage oncology clinical products: Sodium Thiosulfate (STS) and
    Eniluracil (EU)

    –STSata from two Phase 3 trials expected to be presented at ASCO in Q2 2014
    »pending favorable outcome from both studies-file NDA
    –EU: pending partnering discussions- advance to Phase 3

    Phase 3 trial conducted by SIOPEL6 in children with liver cancer 86/102 patients enrolled with interim safety data expected to be presented at ASCO Q2 2014

    No approved treatment: Adherex has been developing STS since 2003
    •Received Orphan Drug Designation in 2004 with 7.5 years exclusivity upon approval

  3. Default

    The two Phase 3 clinical trials studying Sodium Thiosulfate (STS) for prevention of hearing loss in children receiving cisplatin chemotherapy have progressed well. The US based Children Oncology Group (COG) ACCL0431 study completed enrollment in February 2012. Final data is expected to be released by COG during American Society of Clinical Oncology (ASCO) meeting in June 2014.

    The enrollment of the European based SIOPEL 6 Study is almost complete, as 96 out of planned 102 patients have been randomized. The first three interim safety analyses were conducted after 20, 40 and 60 patients, and in each case, the Independent Data Monitoring Committee (IDMC) has recommended continuation of the study. An additional interim safety analysis for 80 patients is also expected to be performed shortly. Safety review data from this study have been submitted for presentation at ASCO in June 2014.

    "We are encouraged by the recent strong patient participation in SIOPEL 6 and the continued recommendation by the IDMC that the study continue. In the event, that data from COG and SIOPEL show compelling results, Adherex plans to discuss the regulatory filing strategy for a New Drug Application (NDA) with the FDA during the second half of 2014" stated Mr. Rosty Raykov, Chief Executive Officer of Adherex.



Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts